Yazar "Bayir, Gulden" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Analysis of early and last effects concomittant chemoradiotherapy of 24 patients with locally advanced cervical carcinoma (lacc)
    (Oxford Univ Press, 2004) Tokatli, Fusun; Uygun, Kazim; Ibis, Kamuran; Bayir, Gulden; Denizli, Bengu; Uzal, Cem
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Bilateral choroidal metastases as an initial manifestation of small-cell carcinoma of the lung
    (Turkish Assoc Tuberculosis & Thorax, 2006) Kocak, Zafer; Tabakoglu, Erhan; Benian, Omer; Bayir, Gulden; Unlu, Ercument; Uzal, Cem
    The occurence of clinically symptomatic intraocular metastases as an initial manifestation of primary neoplasm is rare event. The recognition of metastatic ocular tumors is important since they indicate a poor prognosis. Prompt diagnosis and treatment can significantly improve the quality of life for these patients. We report the case of a 48-year-old man presenting with a two-week history of left sided intraocular pain with blurring of vision and headache, which are the first signs of small-cell lung carcinoma.
  • Küçük Resim Yok
    Öğe
    The effect of low molecular weight heparin on survival in patients with cancer
    (Kare Publ, 2006) Saynak, Mert; Yurut-Caloglu, Vuslat; Bayir, Gulden; Caloglu, Murat; Uzal, Cem
    The association between cancer and venous thromboembolism (VTE) is well established. Of all new venous tromboembolism, approximately 20% are associated with active malignancy. In these cases, the pathogenic mechanisms of thrombosis involve a complex interaction between tumour cells, the haemostatic system, and charateristics of the patient. Anticoagulants are the mainstay therapy for the prevention and treatment of acute VTE. The natural history of VTE is more agressive and anticoagulant treatment failure is more frequent in cancer patients than in patients without cancer. Recently, the results of new prospective randomized clinical trials to evaluate the effect of low-molecular-weight heparin on cancer survival have become available. The results suggest a benefit from treatment, particularly in patients with nonadvanced disease. However, these results are not conclusive and require further research.